California-based biopharmaceutical company Orexigen Therapeutics, Inc. failed to pass our FRISK® score inspection for years, ultimately filing for bankruptcy in early 2018.
Resources
Stay ahead of public company risk with our bankruptcy case studies, high risk reports, blogs and more.